Open and Exploratory Trial to Investigate the Pharmacokinetic of Ceftobiprole Medocaril in Patients With CSF Device
Status:
Completed
Trial end date:
2019-11-04
Target enrollment:
Participant gender:
Summary
Ceftobiprole is a very active new cephalosporin on staphylococci resistant to methicillin
(SEMR: Staphylococcus epidermidis Resistant to Meticillin, SAMR: Staphylococcus aureus
Resistant to Meticillin) and / or vancomycin; it is also very active on pneumococci resistant
to penicillin and / or 3rd generation cephalosporins. This new drug has AMM in nosocomial
respiratory infections, Animal work shows the efficacy of ceftobiprole in gram negative
bacillus meningeal infections.
The rationale of this study is based on the antibacterial spectrum of ceftobiprole, which
would therefore be useful in the treatment of staphylococcal bacterial meningitis resistant
patients (SEMR or SAMR) encountered in intensive care and / or neurosurgery and in the
treatment of pneumococcal meningitis.
To validate these possibilities, it is necessary to know the concentrations of ceftobiprole
in the meningeal space.